Compare Incyte Corporation (INCY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Royal Bank of Canada — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Royal Bank of Canada trades at $210.44 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 11.9× Incyte Corporation's market cap, and Royal Bank of Canada pays a 2.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RY | |
|---|---|---|
Market Cap | $24.54B | $292.32B |
Sector | Health | Financials |
52-Week High | $129.93 | $217.87 |
52-Week Low | $81.61 | $134.80 |
Enterprise Value | $20.04B | — |
Dividend Yield | — | 2.37% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
